Incyte
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 2.5K
- Market Cap
- $12.6B
- Introduction
Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas. The company was founded in April 1991 and is headquartered in Wilmington, DE.
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of INCB160058 When Administered Orally to Healthy Adult Participant
- Conditions
- Healthy Participants
- Interventions
- First Posted Date
- 2024-01-19
- Last Posted Date
- 2025-03-14
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 180
- Registration Number
- NCT06213818
- Locations
- 🇦🇺
Nucleus Network Pty Ltd, Melbourne, Victoria, Australia
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
- Conditions
- Solid Tumors
- Interventions
- First Posted Date
- 2023-12-21
- Last Posted Date
- 2025-06-22
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 466
- Registration Number
- NCT06179160
- Locations
- 🇺🇸
Mayo Clinic Hospital, Phoenix, Arizona, United States
🇺🇸Stanford University, Palo Alto, California, United States
🇺🇸UCLA Healthcare Hematology-Oncology, Santa Monica, California, United States
A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V2)
- Conditions
- NonSegmental Vitiligo
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-11-02
- Last Posted Date
- 2025-03-20
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 450
- Registration Number
- NCT06113471
- Locations
- 🇺🇸
University of Alabama At Birmingham Hospital-Whitaker Clinic, Birmingham, Alabama, United States
🇺🇸C2 Research Center, Llc, Montgomery, Alabama, United States
🇺🇸First Oc Dermatology Research Inc, Fountain Valley, California, United States
A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V1)
- Conditions
- NonSegmental Vitiligo
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-11-02
- Last Posted Date
- 2025-03-27
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 467
- Registration Number
- NCT06113445
- Locations
- 🇺🇸
Cahaba Dermatology, Hoover, Alabama, United States
🇺🇸University of California Irvine, Irvine, California, United States
🇺🇸Clinical Science Institute Clinical Research Specialists Inc, Santa Monica, California, United States
A Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation
- Conditions
- Advanced Solid Tumors
- Interventions
- First Posted Date
- 2023-09-15
- Last Posted Date
- 2025-05-02
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 6
- Registration Number
- NCT06039384
- Locations
- 🇺🇸
Valkyrie Clinical Trials, Los Angeles, California, United States
🇺🇸Banner Md Anderson Cancer Center, Greeley, Colorado, United States
🇺🇸Henry Ford Health System, Detroit, Michigan, United States
A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
- Conditions
- Myeloproliferative Neoplasms
- Interventions
- First Posted Date
- 2023-09-13
- Last Posted Date
- 2025-05-29
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 230
- Registration Number
- NCT06034002
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
🇺🇸Stanford Cancer Institute, Palo Alto, California, United States
🇺🇸University of Miami Health System, Miami, Florida, United States
A Study of INCB099280 in Combination With Axitinib in Adults With Advanced Solid Tumors
- Conditions
- Advanced Solid Tumors
- Interventions
- First Posted Date
- 2023-07-18
- Last Posted Date
- 2025-07-02
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 5
- Registration Number
- NCT05949632
- Locations
- 🇬🇧
Addenbrookes Hospital, Cambridge, United Kingdom
🇬🇧Beatson West of Scotland Cancer Centrewester, Glasgow, United Kingdom
🇬🇧St Bartholomew'S Hospital, London, United Kingdom
A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
- Conditions
- Myeloproliferative Neoplasms
- Interventions
- First Posted Date
- 2023-07-07
- Last Posted Date
- 2025-06-22
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 225
- Registration Number
- NCT05936359
- Locations
- 🇮🇹
Aou Policlinico S. Orsola-Malpighi, Bologna, Italy
🇦🇺Royal Brisbane and Women'S Hospital, Herston, Queensland, Australia
🇦🇺Royal Adelaide Hospital, Adelaide, South Australia, Australia
Study Evaluating the Efficacy and Safety of Povorcitinib in Adults With Chronic Spontaneous Urticaria
- Conditions
- UrticariaHivesAngioedemaPruritisChronic Spontaneous UrticariaChronic Idiopathic Urticaria
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-07-07
- Last Posted Date
- 2025-04-03
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 136
- Registration Number
- NCT05936567
- Locations
- 🇺🇸
Clinical Research Center of Alabama, Birmingham, Alabama, United States
🇺🇸Cahaba Dermatology, Birmingham, Alabama, United States
🇺🇸Foothills Research Center, Scottsdale, Arizona, United States
Observational Study for Patients at Risk for Chronic Graft-Versus-Host Disease
- Conditions
- cGVHD
- Interventions
- Other: Non-Interventional
- First Posted Date
- 2023-06-26
- Last Posted Date
- 2025-06-22
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 1500
- Registration Number
- NCT05919511
- Locations
- 🇺🇸
University of Alabama Birmingham, Birmingham, Alabama, United States
🇺🇸Mayo Clinic Arizona, Phoenix, Arizona, United States
🇺🇸City of Hope, Duarte, California, United States